You have 9 free searches left this month | for more free features.

Alemtuzumab

Showing 1 - 25 of 419

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

Reduced-dose Alemtuzumab for Kidney Transplant Rejection

Not yet recruiting
  • Kidney Transplant Rejection
    • (no location specified)
    Oct 25, 2023

    Predict T Cell Chimerism After MSD SCT for SCD?

    Recruiting
    • Sickle Cell Disease
    • Alemtuzumab Injection [Campath]
    • Amsterdam, Netherlands
      Amsterdam Medical Centre
    Jun 20, 2023

    Allogeneic Hematopoietic Cell Transplantation Trial (Alemtuzumab)

    Not yet recruiting
    • Allogeneic Hematopoietic Cell Transplantation
    • Alemtuzumab
    • (no location specified)
    Aug 12, 2022

    CLL, SLL Trial in Boston (Ofatumumab, High-Dose Methylprednisolone, Alemtuzumab)

    Terminated
    • CLL
    • SLL
    • Boston, Massachusetts
    • +1 more
    Jan 30, 2023

    Hodgkin Lymphoma, DLBCL Trial run by the NCI (campath, Rituximab, EPOCH)

    Completed
    • Hodgkin Lymphoma
    • Diffuse Large B-Cell Lymphoma
    • Campath
    • +2 more
    • Bethesda, Maryland
      National Institutes of Health Clinical Center, 9000 Rockville Pi
    Sep 11, 2022

    T-cell-prolymphocytic Leukemia Trial in Cologne (Fludarabine, Mitoxantrone, Cyclophosphamide and Alemtuzumab, Alemtuzumab)

    Completed
    • T-cell-prolymphocytic Leukemia
    • Fludarabine, Mitoxantrone, Cyclophosphamide and Alemtuzumab
    • Alemtuzumab
    • Cologne, Germany
      University Hospital Cologne
    Dec 16, 2021

    Chronic Granulomatous Disease Trial run by the NIAID (Sirolimus, Cyclophosphamide, Alemtuzumab)

    Recruiting
    • Chronic Granulomatous Disease
    • Bethesda, Maryland
      National Institutes of Health Clinical Center
    Jul 23, 2022

    Leukemia Trial in Houston (Alemtuzumab, Etoposide, Dexamethasone)

    Active, not recruiting
    • Leukemia
    • Alemtuzumab
    • +5 more
    • Houston, Texas
      University of Texas MD Anderson Cancer Center
    Feb 2, 2022

    B-cell Chronic Lymphocytic Leukemia Trial in Peking (Alemtuzumab)

    Suspended
    • B-cell Chronic Lymphocytic Leukemia
    • Alemtuzumab
    • Peking, Beijing, China
      Peking University Cancer Hospital
    Jun 15, 2022

    Relapsing-Remitting Multiple Sclerosis Trial in Hamburg, Mannheim (Autologous Hematopoietic Stem Cell Transplantation,

    Terminated
    • Relapsing-Remitting Multiple Sclerosis
    • Autologous Hematopoietic Stem Cell Transplantation
    • +2 more
    • Hamburg, Germany
    • +1 more
    Mar 1, 2022

    B-Cell Prolymphocytic Leukemia, Chronic Lymphocytic Leukemia, Peripheral T-Cell Lymphoma Trial in Columbus (Letermovir)

    Recruiting
    • B-Cell Prolymphocytic Leukemia
    • +5 more
    • Columbus, Ohio
      Ohio State University Comprehensive Cancer Center
    Nov 18, 2022

    Multiple Sclerosis (MS) Trial in Dallas (Alemtuzumab)

    Completed
    • Multiple Sclerosis (MS)
    • Alemtuzumab
    • Dallas, Texas
    • +1 more
    Jan 24, 2022

    T-Cell Lymphoma Relapsed, Adult T-Cell Leukemia (ATL), Peripheral T-Cell Lymphoma (PTCL) Trial run by the NCI (IL-15 plus,

    Completed
    • T-Cell Lymphoma Relapsed
    • +4 more
    • IL-15 plus
    • alemtuzumab
    • Bethesda, Maryland
      National Institutes of Health Clinical Center, 9000 Rockville Pi
    Apr 27, 2022

    Leukemia, Lymphocytic, Chronic, B-Cell Trial in Austria (Bendamustine, Alemtuzumab)

    Completed
    • Leukemia, Lymphocytic, Chronic, B-Cell
    • Innsbruck, Tirol, Austria
    • +6 more
    Feb 15, 2022

    Multiple Sclerosis, Relapsing-Remitting Trial in Münster (Alemtuzumab)

    Completed
    • Multiple Sclerosis, Relapsing-Remitting
    • Alemtuzumab
    • Münster, Germany
      Universitätsklinikum Münster, Klinik für Allgemeine Neurologie
    Oct 25, 2021

    Adding Azathioprine/Hydroxyurea Preconditioning to

    Recruiting
    • Sickle Cell Disease
    • Preconditioning with azathiprine and hydroxyurea (3 months)
    • Amsterdam, Netherlands
      Amsterdam Medical Centre
    Feb 9, 2022

    Lymphoma, T-Cell, Lymphoma, Extranodal NK-T-Cell Trial run by the NCI (Alemtuzumab (Campath), EPOCH)

    Completed
    • Lymphoma, T-Cell
    • Lymphoma, Extranodal NK-T-Cell
    • Bethesda, Maryland
      National Institutes of Health Clinical Center, 9000 Rockville Pi
    Feb 3, 2022

    Sickle Cell Disease Trial in Duarte (drug, procedure, radiation)

    Recruiting
    • Sickle Cell Disease
    • Alemtuzumab
    • +3 more
    • Duarte, California
      City of Hope Comprehensive Cancer Center
    Jul 31, 2022

    Sickle Cell Disease Trial in Memphis (hydroxyurea, azathioprine, alemtuzumab, thioptepa, low dose total body irradiation and

    Recruiting
    • Sickle Cell Disease
    • hydroxyurea, azathioprine, alemtuzumab, thioptepa, low dose total body irradiation and sirolimus
    • hydroxyurea, azathioprine, alemtuzumab, thiotepa, plerixafor, low dose total body irradiation, cyclophosphamide and sirolimus
    • Memphis, Tennessee
      St. Jude Children's Research Hospital
    May 5, 2022

    Czech Pharmaco-epidemiological Study on Disease Modifying Drugs

    Completed
    • Multiple Sclerosis
    • interferons, glatiramer acetate, teriflunomide, dimethyl fumarate, alemtuzumab, cladribine, fingolimod, ponesimod, rituximab, ocrelizumab, ofatumumab, natalizumab
    • Prague, Czechia
      IMPULS Endowment Fund
    Mar 7, 2023

    Sickle Cell Disease Trial in Hackensack (Alemtuzumab, Fludarabine, Melphalan)

    Active, not recruiting
    • Sickle Cell Disease
    • Alemtuzumab
    • +3 more
    • Hackensack, New Jersey
      Hackensack University Medical Center
    Feb 4, 2022

    Multiple Sclerosis Trial in Worldwide (Alemtuzumab GZ402673, Glatiramer acetate, Beta-Interferon)

    Active, not recruiting
    • Multiple Sclerosis
    • Alemtuzumab GZ402673
    • +11 more
    • Wien, Austria
    • +20 more
    Jun 16, 2022

    Assess Pregnancy Outcomes in Women Exposed to Diroximel Fumarate

    Recruiting
    • Multiple Sclerosis
    • Diroximel Fumarate
    • +8 more
    • Eden Prairie, Minnesota
      OptumInsight
    Jan 9, 2023

    Multiple Sclerosis Trial in Ramat Gan (COVID-19 vaccination)

    Recruiting
    • Multiple Sclerosis
    • COVID-19 vaccination
    • Ramat Gan, Israel
      Sheba Medical Center
    Oct 6, 2021

    Sickle Cell Anemia Trial run by the NHLBI (PBSC Transplant, Alemtuzumab, Sirolimus)

    Active, not recruiting
    • Sickle Cell Anemia
    • PBSC Transplant
    • +4 more
    • Bethesda, Maryland
      National Institutes of Health Clinical Center, 9000 Rockville Pi
    Oct 13, 2022